Skip to content

Clinical study on the treatment of myocardial remodeling after acute myocardial infarction by integrated traditional Chinese and western medicine

Clinical study on the treatment of myocardial remodeling after acute myocardial infarction by integrated traditional Chinese and western medicine

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005045
Enrollment
Unknown
Registered
2021-07-12
Start date
2021-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 30 to 75 years; 2. Emergency admission STEMI patients who meet the 4th edition of the global definition of AMI (cTnI peak value > 99% upper limit of the reference value (URL) and have an ascending and descending curve, and have clinical evidence of myocardial ischemia. 3. All patients have received emergency PCI, and the infarct-related arterial TIMI blood flow classification has reached grade 3, within 10 days after PCI; 4. Voluntarily participate in this study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. AMI combined with severe acute heart failure uncontrolled; 2. AMI combined with cardiogenic shock (Killip grade >= grade III), who did not respond to vasopressors; 3. AMI complicated with severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation), second-degree or higher atrioventricular block, and rapid atrial fibrillation; 4. AMI complicated with mechanical complications (ventricular septal perforation, papillary muscle rupture, cardiac thrombus, ventricular free wall rupture); 5. Severe systemic diseases (severe infection, massive hemorrhage due to anticoagulation and antithrombotics, respiratory failure); 6. History of cerebral hemorrhage and cerebral aneurysm within 3 months; 7. Severe hepatic and renal insufficiency [ALT >= 3 ULN (Upper Limit of Normal), Cr > 134µmol/L (2mg/dl) or eGFR < 45ml/min/1.73m2]. 8. Patients with neuropsychiatric diseases; 9. Malignant tumor; 10. Other pathophysiological states with expected survival less than 1 year; 11. Those who are allergic to the components of the drug in this study; 12. Pregnant or lactating women; 13. Patients who participated in other clinical studies of traditional Chinese medicine within the first three months; 14. Other diseases of clinical significance, etc., may cause serious danger to the patient.

Design outcomes

Primary

MeasureTime frame
Left ventricular end-diastolic volume;Left ventricular end-systolic volume;

Secondary

MeasureTime frame
Global longitudinal strain of left ventricle;Incidence of compound end points of cardiovascular events;left ventricular ejection fraction;left atrial volume;Global longitudinal strain of left atrium;

Countries

China

Contacts

Public ContactZhang Mei

Qilu Hospital of Shandong University

daixh@vip.sina.com+86 18560086629

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026